Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · February 27, 2023

Efficacy and Safety of Dapagliflozin According to Sex in Patients With Heart Failure Across the Range of LVEF



Additional Info

Disclosure statements are available on the authors' profiles:

Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
Circulation 2022 Nov 07;[EPub Ahead of Print], X Wang, M Vaduganathan, BL Claggett, SM Hegde, M Pabon, IJ Kulac, O Vardeny, E O'Meara, S Zieroth, T Katova, MM McGrath, AC Pouleur, PS Jhund, AS Desai, SE Inzucchi, MN Kosiborod, RA de Boer, L Køber, MS Sabatine, FA Martinez, P Ponikowski, SJ Shah, AF Hernandez, AM Langkilde, JJV McMurray, SD Solomon, CSP Lam

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading